GRIFFIN MICHELLE RENEE 4

What Happened
Michelle Griffin, a director of Adaptive Biotechnologies (ADPT), sold 15,394 shares in an open-market transaction on March 11, 2026. The reported weighted-average sale price was $13.91 per share, for a total value of approximately $214,131. This was a sale (not a purchase or award) and is typically considered routine insider selling rather than a direct signal of company prospects.

Key Details

• Transaction date: March 11, 2026; Form 4 filed: March 13, 2026 (filed within the usual 2-business-day window).
• Shares sold: 15,394; weighted-average price: $13.91; total value: ~$214,131.
• Price range reported in footnote: individual trades ranged from $13.84 to $13.96; the reporting person offers to provide a breakdown of the number of shares sold at each price upon request (Footnote F1).
• Shares owned after the transaction: Not specified in the information provided.
• Filing timeliness: Appears timely (filed two days after the transaction); no 10b5-1 plan or tax-withholding notes disclosed in the provided excerpt.

Context
Sales by company directors are common and can be for many personal reasons (liquidity, diversification, tax planning). This single open-market sale should be viewed as factual disclosure rather than a definitive statement about company fundamentals.